Overexpression of SH2D1A promotes cancer progression and is associated with immune cell infiltration in hepatocellular carcinoma via bioinformatics and in vitro study.
Hepatocellular carcinoma
Immune microenvironment
Prognosis
SH2 domain containing 1A
The Cancer Genome Atlas
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
19 Oct 2023
19 Oct 2023
Historique:
received:
27
11
2022
accepted:
18
08
2023
medline:
23
10
2023
pubmed:
20
10
2023
entrez:
19
10
2023
Statut:
epublish
Résumé
SH2 domain containing 1A (SH2D1A) expression has been linked to cancer progression. However, the functions of SH2D1A in hepatocellular carcinoma (HCC) have not been reported. The effects of SH2D1A on the proliferation, migration, and invasion of HCC cells and the related pathways were re-explored in cell models with SH2D1A overexpression using the CCK-8, migration and invasion assays and western blotting. The functions and mechanisms of genes co-expressed with SH2D1A were analyzed using gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. The relationship between SH2D1A expression and immune microenvironment features in HCC was explored. Elevated SH2D1A expression promoted cell proliferation, migration, and invasion, which was related to the overexpression of p-Nf-κB and BCL2A1 protein levels in HCC. SH2D1A expression was related to the immune, stromal, and ESTIMATE scores, and the abundance of immune cells, such as B cells, CD8 SH2D1A overexpression was found to promote cell growth and metastasis via the Nf-κB signaling pathway and may be related to the immune microenvironment in HCC. The findings indicate that SH2D1A can function as a biomarker in HCC.
Sections du résumé
BACKGROUND
BACKGROUND
SH2 domain containing 1A (SH2D1A) expression has been linked to cancer progression. However, the functions of SH2D1A in hepatocellular carcinoma (HCC) have not been reported.
METHODS
METHODS
The effects of SH2D1A on the proliferation, migration, and invasion of HCC cells and the related pathways were re-explored in cell models with SH2D1A overexpression using the CCK-8, migration and invasion assays and western blotting. The functions and mechanisms of genes co-expressed with SH2D1A were analyzed using gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. The relationship between SH2D1A expression and immune microenvironment features in HCC was explored.
RESULTS
RESULTS
Elevated SH2D1A expression promoted cell proliferation, migration, and invasion, which was related to the overexpression of p-Nf-κB and BCL2A1 protein levels in HCC. SH2D1A expression was related to the immune, stromal, and ESTIMATE scores, and the abundance of immune cells, such as B cells, CD8
CONCLUSION
CONCLUSIONS
SH2D1A overexpression was found to promote cell growth and metastasis via the Nf-κB signaling pathway and may be related to the immune microenvironment in HCC. The findings indicate that SH2D1A can function as a biomarker in HCC.
Identifiants
pubmed: 37858067
doi: 10.1186/s12885-023-11315-1
pii: 10.1186/s12885-023-11315-1
pmc: PMC10585762
doi:
Substances chimiques
Biomarkers, Tumor
0
NF-kappa B
0
SH2D1A protein, human
0
Signaling Lymphocytic Activation Molecule Associated Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1005Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Yang J, Wang B, Xu Q, Yang Y, Hou L, Yin K, Guo Q, Hua Y, Zhang L, Li Y, et al. TMEM166 inhibits cell proliferation, migration and invasion in hepatocellular carcinoma via upregulating TP53. Mol Cell Biochem. 2021;476(2):1151–63.
doi: 10.1007/s11010-020-03979-1
pubmed: 33200377
Li D, Ji YM, Guo JL, Guo Q. Upregulated expression of MTFR2 as a novel biomarker predicts poor prognosis in hepatocellular carcinoma by bioinformatics analysis. Future Oncol. 2021;17:3187–201.
doi: 10.2217/fon-2020-1160
pubmed: 34156259
Liang Y, Luo H, Zhang H, Dong Y, Bao Y. Oncogene Delta/Notch-Like EGF-Related Receptor Promotes Cell Proliferation, Invasion, and Migration in Hepatocellular Carcinoma and Predicts a Poor Prognosis. Cancer Biother Radiopharm. 2018;33(9):380–6.
pubmed: 30235011
pmcid: 6241329
Shi M, Lv X, Zhu M, Dong Y, Hu L, Qian Y, Fan C, Tian N. HMGA1 promotes hepatocellular carcinoma proliferation, migration, and regulates cell cycle via miR-195-5p. Anticancer Drugs. 2022;33(1):e273–85.
doi: 10.1097/CAD.0000000000001201
pubmed: 34407055
Xu Z, Peng B, Liang Q, Chen X, Cai Y, Zeng S, Gao K, Wang X, Yi Q, Gong Z, et al. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma. Front Immunol. 2021;12:719175.
doi: 10.3389/fimmu.2021.719175
pubmed: 34603293
pmcid: 8484522
Liu R, Wang G, Zhang C, Bai D. A prognostic model for hepatocellular carcinoma based on apoptosis-related genes. World J Surg Oncol. 2021;19(1):70.
doi: 10.1186/s12957-021-02175-9
pubmed: 33712023
pmcid: 7955636
Li F, Li K, Li D, Zhang W, Yang KW, Ke D, Guo Q, Shi RS. ATG10 overexpression is related to the dismal prognosis and promotes the growth and migration of hepatocellular carcinoma cells via cyclin B1/CDK1 and CDK2. Am J Cancer Res. 2023;13(4):1188–208.
pubmed: 37168332
pmcid: 10164811
Tang X, Huang X, Wang D, Yan R, Lu F, Cheng C, Li Y, Xu J. Identifying gene modules of thyroid cancer associated with pathological stage by weighted gene co-expression network analysis. Gene. 2019;704:142–8.
doi: 10.1016/j.gene.2019.04.017
pubmed: 30965127
Zhang Z, Luo A, Zeng Z, Zhou Y, Wu W. Identification of hub genes and functional modules in colon adenocarcinoma based on public databases by bioinformatics analysis. J Gastrointest Oncol. 2021;12(4):1613–24.
doi: 10.21037/jgo-21-415
pubmed: 34532115
pmcid: 8421865
Zhu XJ, Jin X, Dai L, Liu X, Liu Z. ATG4 promotes cell proliferation, migration and invasion in HCC and predicts a poor prognosis. Eur Rev Med Pharmacol Sci. 2020;24(24):12686–93.
pubmed: 33378015
Huang K, Xie W, Wang S, Li Q, Wei X, Chen B, Hua Y, Li S, Peng B, Shen S. High SPINK1 Expression Predicts Poor Prognosis and Promotes Cell Proliferation and Metastasis of Hepatocellular Carcinoma. J Invest Surg. 2021;34(9):1011–20.
doi: 10.1080/08941939.2020.1728443
pubmed: 32066292
Wang G, Zhou H, Gu Z, Gao Q, Shen G. Oct4 promotes cancer cell proliferation and migration and leads to poor prognosis associated with the survivin/STAT3 pathway in hepatocellular carcinoma. Oncol Rep. 2018;40(2):979–87.
pubmed: 29901157
Sumazaki R, Kanegane H, Osaki M, Fukushima T, Tsuchida M, Matsukura H, Shinozaki K, Kimura H, Matsui A, Miyawaki T. SH2D1A mutations in Japanese males with severe Epstein-Barr virus–associated illnesses. Blood. 2001;98(4):1268–70.
doi: 10.1182/blood.V98.4.1268
pubmed: 11493483
Torralba-Raga L, Tesi B, Chiang SCC, Schlums H, Nordenskjöld M, Horne A, Henter JI, Meeths M, Abdelhaleem M, Weitzman S, et al. Diagnostic challenges for a novel SH2D1A mutation associated with X-linked lymphoproliferative disease. Pediatr Blood Cancer. 2020;67(4):e28184.
doi: 10.1002/pbc.28184
pubmed: 31994322
Koochakzadeh L, Hosseinverdi S, Hedayat M, Farahani F, Tofighi A, Eghbali M, Bidoki AZ, Izadyar M, Rahiminejad MS, Ramyar A, et al. Study of SH2D1A gene mutation in paediatric patients with B-cell lymphoma. Allergol Immunopathol (Madr). 2015;43(6):568–70.
doi: 10.1016/j.aller.2015.01.007
pubmed: 25982576
Liang JH, Zhu HY, Xu DM, Wang L, Wang Y, Qiao C, Wu YJ, Wang R, Li JY, Xu W. A new SH2D1A mutation in a female adult XLP disease with hemophagocytic lymphohistiocytosis and NK-cell leukemia. Ann Hematol. 2019;98(12):2829–31.
doi: 10.1007/s00277-019-03810-y
pubmed: 31758261
Zhou X, Chen D, Yan Y, Li Q, Xing W, Liu Y, Chen Y, Wang D, Yuan Y, Xie J, Zeng W, Pan J. The nociceptin receptor promotes autophagy through Nf-κB signaling and is transcriptionally regulated by E2F1 in HCC. Cell Death Discov. 2022;8(1):165.
doi: 10.1038/s41420-022-00978-7
pubmed: 35383175
pmcid: 8983730
Chen L, Lin X, Lei Y, Xu X, Zhou Q, Chen Y, Liu H, Jiang J, Yang Y, Zheng F, Wu B. Aerobic glycolysis enhances HBx-initiated hepatocellular carcinogenesis via NF-κBp65/HK2 signalling. J Exp Clin Cancer Res. 2022;41(1):329.
doi: 10.1186/s13046-022-02531-x
pubmed: 36411480
pmcid: 9677649
Hu B, Xu Y, Li YC, Huang JF, Cheng JW, Guo W, Yin Y, Gao Y, Wang PX, Wu SY, Zhou J, Fan J, Yang XR. CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF-κB oncogenic signaling. Clin Transl Med. 2020;10(8):e233.
doi: 10.1002/ctm2.233
pubmed: 33377659
pmcid: 7708822
Yang Q, Zhang J, Xu S, Jia C, Meng W, Tang H, Zhang X, Zhang Y, Fu B. Knockdown of PHF5A Inhibits Migration and Invasion of HCC Cells via Downregulating NF-κB Signaling. Biomed Res Int. 2019;2019:1621854.
pubmed: 30766880
pmcid: 6350539
Yang W, Yang S, Zhang M, Gao D, He T, Guo M. ZNF545 suppresses human hepatocellular carcinoma growth by inhibiting Nf-κB signaling. Genes Cancer. 2017;8(3–4):528–35.
doi: 10.18632/genesandcancer.137
pubmed: 28680537
pmcid: 5489650
Wang D, Hu X, Xiao L, Long G, Yao L, Wang Z, Zhou L. Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC. J Gastrointest Surg. 2021;25(2):421–7.
doi: 10.1007/s11605-019-04492-7
pubmed: 32026332
Shi J, Liu J, Tu X, Li B, Tong Z, Wang T, Zheng Y, Shi H, Zeng X, Chen W, et al. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. J Immunother Cancer. 2022;10(1):e003133.
doi: 10.1136/jitc-2021-003133
pubmed: 35101942
pmcid: 8804705
Mahn R, Vogt A, Kupczyk P, Sadeghlar F, van Beekum K, Hüneburg R, Meyer C, Toma M, Ahmadzadehfar H, Essler M, et al. Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience. Scand J Gastroenterol. 2020;55(9):1057–62.
doi: 10.1080/00365521.2020.1794539
pubmed: 32692941
Liu X, Li M, Wang X, Dang Z, Jiang Y, Wang X, Kong Y, Yang Z. PD-1+ TIGIT+ CD8+ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma. Cancer Immunol Immunother. 2019;68(12):2041–54.
doi: 10.1007/s00262-019-02426-5
pubmed: 31720814